HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Abstract
Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this multicenter, registry-based study, we analyzed outcomes of 378 patients undergoing first allo-HCT between 2006-2017 for t-MN arising secondary to lymphoma treatment. Median age was 58 years at allo-HCT; 222 (59%) had a diagnosis of t-MDS and 156 (41%) of t-AML, respectively. At the time of allo-HCT, 46% of t-MN cases were reported as in complete remission (CR) and 15% of lymphomas were recorded as not in remission. A reduced intensity conditioning regimen was used in 70% of cases. For the entire cohort, 5-year OS, and t-MN PFS, relapse incidence and NRM were 32%, 28%, 35% and 37%, respectively. In multivariable analysis, undergoing allo-HCT with t-MN not in CR and older age were associated with significantly worse OS, PFS and NRM. At 5 years post allo-HCT, the relapse incidence of lymphoma was low at 3%, while the rate of secondary malignancies was 8%. This analysis shows the curative potential of allo-HCT for patients with t-MN arising secondary to lymphoma treatment in approximately a third of patients.
AuthorsMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, Uwe Platzbecker, Katja Sockel, Jürgen Finke, Nicolaus Kröger, Edouard Forcade, Arnon Nagler, Matthias Eder, Johanna Tischer, Annoek E C Broers, Jürgen Kuball, Keith M O Wilson, Mathilde Hunault-Berger, Matthew Collin, Domenico Russo, Lucía López Corral, Grzegorz Helbig, Alberto Mussetti, Christof Scheid, Carmelo Gurnari, Kavita Raj, Joanna Drozd-Sokolowska, Ibrahim Yakoub-Agha, Marie Robin, Donal P McLornan
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 59 Issue 3 Pg. 395-402 (Mar 2024) ISSN: 1476-5365 [Electronic] England
PMID38195984 (Publication Type: Multicenter Study, Journal Article)
Copyright© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Topics
  • Humans
  • Middle Aged
  • Retrospective Studies
  • Leukemia, Myeloid, Acute (therapy)
  • Lymphoma (etiology, therapy)
  • Recurrence
  • Transplantation Conditioning
  • Neoplasms, Second Primary (etiology)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Graft vs Host Disease (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: